2 Penny Stocks Popping on Partnerships

JBLU is eyeing its lowest close in months after lowering its third-quarter RASM outlook

Digital Content Manager
Sep 4, 2019 at 1:28 PM
facebook twitter linkedin


Stocks have made a comeback today, led by big gains in the energy sector. Three specific stocks making notable moves are healthcare names Clearside Biomedical Inc (NASDAQ:CLSD) and Idera Pharmaceuticals Inc (NASDAQ:IDRA), as well as flight concern JetBlue Airways Corporation (NASDAQ:JBLU). Below, we'll take a look at what's driving the shares of CLSD, IDRA, and JBLU. 

CLSD Stock Surges On Regenxbio Partnership

The shares of long-suffering Clearside Biomedical are getting a boost today, after the ocular therapy concern inked a licensing agreement Regenxbio (RGNX). The agreement will give RGNX exclusive rights to CLSD's proprietary microinjector for direct delivery of its new gene therapy drug, RGX-314. 

CLSD shares are up 22.4% to trade at $0.72. This pop comes just days after the penny stock suffered a massive 38.2% drop on Aug. 22, in reaction to the Food and Drug Administration's (FDA) rejection of the company's eye drug, Xipere. The stock bottomed at an all-time low of $0.56 just a few days later. While CLSD is pacing for its first close atop its 10-day moving average since gapping lower, it seems to have run out of steam right below previous support at its 20-day trendline.

AbbVie Deal Boosts Idera Stock 

News that Idera Pharmaceuticals will enter into a clinical research partnership with AbbVie (ABBV) has its shares up 10.4% at $2.54. The two drugmakers will collaborate on a study of AbbVie's ABBV-368 treatment, paired with IDRA's experimental tilsotolimod drug, in patients with metastatic head and neck squamous cell carcinoma. 

Since hitting a six-year low of $2.08 on Aug. 15, the security has rallied roughly 22%, and is now eyeing its first close atop its 50-day moving average since July. Short sellers, meanwhile, cashed in during the stock's slide to new lows. Short interest fell 10.6% in the Aug. 1-Aug. 15 reporting period to 830,000 shares -- the fewest since mid-February.

JBLU Stock Sinks on Downwardly Revised RASM Forecast 

JetBlue is taking a hit today, after the company predicted its third-quarter revenue per available seat mile (RASM) growth will range from 2% to flat in the third quarter, versus the previous estimate of 0.5% to 3.5%. The stock has taken a serious beating in recent months, guided lower by its 10-day moving average. In fact, JBLU lost nearly 10% in August -- its biggest one-month drop since December. The stock hit a five-month low of $16.25 earlier, and is now down 4.7% at $16.37. 

Considering JBLU's recent trajectory, it's no surprise that most analysts consider the security a "hold" or worse. However, five of the 14 in coverage still call the airplane name a "strong buy." What's more, the 12-month consensus price target of $21.53 represents a level not touched by JBLU since March 2018, and represents a 31.4% premium to current levels. Should this negative price action continue, a round of bearish analyst notes could add even more pressure on the charts. 

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners